Imiquimod
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
Imiquimod: From No Taiwan-Registered Indication to Pre-malignant Neoplasm
One-Sentence Summary
Imiquimod (DrugBank DB00724) is a topical Toll-like receptor 7 (TLR7) agonist that is not currently marketed in Taiwan (0 TFDA licenses on file), so no original approved indication is available in this evidence pack. The TxGNN model predicts it may be effective for Pre-malignant Neoplasm, and this direction is supported by 19 clinical trials and 9 publications collected in this pack — though only a subset (mainly actinic keratosis, VIN, and CIN studies) directly evaluate imiquimod in this disease category; most other trials use imiquimod as a vaccine adjuvant and are not directly relevant.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — Imiquimod is not currently marketed in Taiwan (0 TFDA licenses on file) |
| Predicted New Indication | Pre-malignant Neoplasm |
| TxGNN Prediction Score | 99.92% (rank 1240 among all predictions) |
| Evidence Level | L1 |
| Taiwan Market Status | Not marketed (Not Marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Structured mechanism-of-action data for Imiquimod is currently a data gap in this evidence pack (DrugBank MOA field not populated — see DG002). Based on the trial and literature evidence collected, however, Imiquimod is known to act as a TLR7 agonist: it activates local innate immunity (inducing IFN-α and other cytokines), which promotes apoptosis of dysplastic keratinocytes.
This mechanism is already an established treatment pathway for several epidermal and mucosal pre-malignant conditions — actinic keratosis, vulvar intraepithelial neoplasia (VIN), and cervical intraepithelial neoplasia (CIN) — all of which fall under the broader “pre-malignant neoplasm” category being predicted here. Because the mechanism is local immune activation rather than tumor-type-specific cytotoxicity, it plausibly generalizes across different pre-malignant epithelial lesions, which is consistent with why multiple Phase 2/3 trials already exist for related conditions even though “pre-malignant neoplasm” as a formal indication has not been evaluated as a single entity.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00175643 | Phase 3 | Completed | 20 | Evaluated duration of effect of imiquimod 5% cream (3x/week, 1–2 cycles) for actinic keratoses on the head |
| NCT03233412 | Phase 2 | Completed | 90 | RCT of topical imiquimod for high-grade cervical intraepithelial lesions (CIN) from persistent HPV 16/18 infection |
| NCT02329171 | Phase 3 | Terminated | 9 | RCT of topical imiquimod vs. LLETZ surgery for high-grade CIN (CIN 2-3); terminated early, small sample |
| NCT04219358 | Phase 1 | Terminated | 49 | Compared 5%, 0.05%, and nanoencapsulated 0.05% imiquimod gel for actinic cheilitis (premalignant lip lesion); terminated |
| NCT02242929 | Phase 3 | Unknown | 145 | Non-inferiority RCT of surgery+imiquimod vs. excision alone for nodular basal cell carcinoma (malignant, borderline relevance) |
| NCT01229319 | Phase 4 | Unknown | 20 | Assessed imiquimod 3.75% cream after cryotherapy for hypertrophic actinic keratoses on hands/forearms |
| NCT00941811 | Phase 2 | Completed | 5 | Explored immune escape mechanisms and efficacy of imiquimod for vulvar intraepithelial neoplasia (VIN 2/3) and anogenital warts |
| NCT01720407 | Phase 3 | Completed | 259 | Neoadjuvant imiquimod to reduce excision size/risk of incomplete excision in lentigo maligna (intraepidermal melanoma) of the face |
| NCT04883645 | Early Phase 1 | Completed | 16 | Pilot trial of neoadjuvant topical imiquimod (Aldara) immunotherapy in early-stage oral squamous cell carcinoma |
Note: 10 additional registered trials use imiquimod solely as a vaccine adjuvant in advanced/malignant cancers (prostate, melanoma, lung, glioma) and are not direct evidence for pre-malignant neoplasm; they are omitted from this table.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23235673 | 2012 | Review | Cochrane Database Syst Rev | Systematic review of interventions (including imiquimod) for anal intraepithelial neoplasia (AIN), an HPV-related pre-malignant condition |
| 21491403 | 2011 | Review | Cochrane Database Syst Rev | Systematic review of medical interventions, including imiquimod, for high-grade vulval intraepithelial neoplasia (VIN) |
| 26516853 | 2015 | Review | Int J Mol Sci | Reviews combined photodynamic therapy approaches for non-melanoma skin cancer and precursor lesions |
| 15584683 | 2004 | Review | Semin Cutan Med Surg | Reviews topical treatment strategies (incl. imiquimod) for non-melanoma skin cancer and precursor lesions |
| 20505896 | 2010 | Review | Skin Therapy Lett | Reviews current management of actinic keratosis, including topical field therapies |
| 29500135 | 2018 | Cohort | Urol Oncol | Rat model PK/PD of TLR7 agonists related to imiquimod for (pre)malignant urothelial lesions |
| 18931984 | 2008 | Case Report | Der Hautarzt | Case of disseminated superficial actinic porokeratosis with coexisting actinic keratoses resistant to topical treatment |
| 30284955 | 2019 | Case Report | Int J STD AIDS | High-grade VIN successfully treated with topical imiquimod 5% in a renal transplant recipient |
| 15601490 | 2004 | Case Report | Int J STD AIDS | Bowenoid papulosis of the penis successfully treated with topical imiquimod 5% cream |
Taiwan Market Information
Imiquimod is not currently marketed in Taiwan — 0 TFDA licenses are on file in this evidence pack, so no authorization number, product name, dosage form, or approved indication text is available.
Safety Considerations
Please refer to the SmPC for safety information. (Key warnings, contraindications, and drug interaction data are not yet available in this evidence pack — resolving this is a blocking data gap, see DG001.)
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple Phase 2/3 trials (including two completed Phase 3 studies) directly support imiquimod’s efficacy in related pre-malignant epithelial lesions (actinic keratosis, VIN, CIN), giving this prediction L1 evidence strength. However, imiquimod is not currently marketed in Taiwan, and drug-level safety labeling and MOA data are still missing, so the recommendation cannot advance to unconditional “Go.”
To proceed, the following is needed:
- TFDA-equivalent safety labeling (key warnings/contraindications) — currently a blocking gap (DG001)
- Confirmed DrugBank/MOA record for formal mechanism-of-action analysis (DG002)
- A regulatory pathway assessment, since Imiquimod holds no existing Taiwan market authorization
- Route/formulation compatibility confirmation (topical route availability against required route for pre-malignant neoplasm indications)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.